Compounded GLP-1s: Why doctors worry and the FDA is cracking down

Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down

The explosive popularity of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and diabetes management has spawned a booming secondary market: compounded versions of these drugs, sold at a fraction of brand-name prices through telehealth platforms, medical spas, and online pharmacies. But as reported by Stanford Medicine (med.stanford.edu), that market is now facing intensified scrutiny from federal regulators and mounting concern from physicians who warn that compounded GLP-1s carry risks that consumers may not fully understand.

The core tension is straightforward. Brand-name GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have been in persistent short supply since demand surged, pushing many patients toward compounded alternatives that are not FDA-approved in the same sense as their brand-name counterparts. Compounding pharmacies are permitted under federal law to create custom formulations of drugs, typically for patients with specific medical needs that commercial products cannot meet, or during officially declared shortages. That legal exception has become the backbone of a rapidly expanding industry now serving millions of Americans seeking cheaper access to weight-loss medications.

Why Physicians Are Sounding the Alarm

According to the Stanford Medicine report, doctors have raised a range of concerns about compounded GLP-1 products, centering on inconsistent quality control, questionable sourcing of active pharmaceutical ingredients, and dosing accuracy. Unlike FDA-approved drugs, which undergo rigorous manufacturing oversight and clinical trials to establish safety and efficacy, compounded medications are not independently verified by the agency before reaching patients.

Key concerns cited by medical professionals include:

• Variability in drug potency between batches, which can lead to underdosing or overdosing
• Use of salt forms of semaglutide or tirzepatide, rather than the base compounds used in FDA-approved products, raising questions about how the body absorbs and processes them
• Limited transparency into the sourcing and purity of active pharmaceutical ingredients, some of which have been traced to overseas suppliers
• Adverse events reported to poison control centers and the FDA linked to dosing errors with compounded injectable products

These concerns are not merely theoretical. The FDA has previously flagged adverse event reports tied to compounded semaglutide, including cases of incorrect dosing that led to hospitalization, underscoring the real-world stakes of a largely unregulated supply chain.

The FDA's Regulatory Response

Federal law generally restricts compounding of drugs that are copies of commercially available, FDA-approved products unless that drug appears on the FDA's official shortage list. For much of the past two years, semaglutide and tirzepatide were listed as being in shortage, which opened the door for compounders to legally produce alternative versions. As manufacturers have ramped up production and the FDA has determined that shortages of these drugs are resolving, that legal justification for widespread compounding is eroding.

The FDA has taken a more assertive posture toward the compounding industry in recent months, warning pharmacies and telehealth companies against continuing to market mass-produced compounded GLP-1s once shortage designations are lifted. The agency has also issued warning letters to companies engaged in what it considers improper marketing practices, including claims that overstate safety or efficacy without adequate substantiation.

Why This Matters for the Peptide Industry

The crackdown extends well beyond GLP-1 drugs themselves and has significant implications for the broader peptide compounding industry, which has grown substantially in recent years. Many of the same 503A and 503B compounding facilities producing semaglutide and tirzepatide also manufacture other peptide-based products, some of which occupy legal gray areas with less established safety data than GLP-1 drugs.

Industry observers note that heightened FDA attention on GLP-1 compounding is likely to translate into broader enforcement scrutiny of peptide compounders generally, including inspections, ingredient sourcing requirements, and marketing restrictions. Pharmacies that built business models around high-volume GLP-1 compounding may need to pivot quickly as shortage-based legal cover disappears.

What This Means for Patients and Providers

For consumers currently using or considering compounded GLP-1 medications, several practical realities are emerging:

• Compounded semaglutide and tirzepatide may become harder to access legally as shortage designations lift and the FDA enforces restrictions more aggressively
• Patients should ask their prescribing pharmacy or telehealth provider about the sourcing and formulation of any compounded product they receive
• Physicians are increasingly advising patients to weigh the cost savings of compounded drugs against documented risks around quality control and dosing consistency
• Insurance coverage, price, and access barriers to brand-name GLP-1 drugs remain a central driver of demand for compounded alternatives, meaning enforcement actions could create supply gaps for lower-income patients

As the Stanford Medicine report suggests, this is not simply a story about drug pricing or convenience. It is fundamentally a story about the limits of regulatory oversight in a fast-moving pharmaceutical market, and about how quickly compounding can shift from a narrow legal safety valve into a large-scale commercial industry operating with far less oversight than traditional drug manufacturing.

What to Watch For

Readers should monitor several developments in the coming months, including whether the FDA formally removes semaglutide and tirzepatide from its shortage list nationwide, how aggressively the agency pursues enforcement against telehealth companies and compounding pharmacies continuing to sell these products, and whether state pharmacy boards move in parallel with federal action. Litigation from compounding industry trade groups challenging FDA shortage determinations is also a possibility, as similar disputes have occurred in the past.

This article is intended for informational purposes only and does not constitute medical or legal advice. Readers with questions about specific medications or treatment options should consult a licensed healthcare provider.